Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug keep your heart in rhythm?

NCT ID NCT07187570

Disease control Sponsor: Region Stockholm Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether dapagliflozin, a drug typically used for diabetes, can prevent atrial fibrillation from coming back after a procedure called cardioversion (an electric shock to restore normal heart rhythm). About 1600 adults with AF will take either dapagliflozin or no extra drug for up to 56 days. Researchers will track heart rhythm using a handheld device to see if the drug reduces recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug that lowers blood sugar and may help heart rhythm)
What this could lead to
If it works, this could offer a new, short-term treatment to prevent atrial fibrillation from coming back after cardioversion.
What could go wrong
This is a phase 3 trial, but it's still early to know if dapagliflozin truly helps AF. The drug may not reduce recurrence, and side effects like dehydration or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date. * Age ≥ 55 years. * Provided written informed consent. Exclusion Criteria: * Current treatment with an SGLT2 inhibitor. * Prior/current diagnosis of heart failure. * Type 1 diabetes mellitus. * Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2. * Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days). * Contraindications to SGLT2 inhibitors. * Any condition or circumstance in which the patient should not participate in the study according to the study investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akademiska sjukhuset

    NOT_YET_RECRUITING

    Uppsala, 75389, Sweden

  • Danderyds Hospital

    NOT_YET_RECRUITING

    Stockholm, 18527, Sweden

  • Karolinska University Hospital

    RECRUITING

    Stockholm, 14186, Sweden

  • Linköping university hosptial

    NOT_YET_RECRUITING

    Linköping, 58225, Sweden

  • Norrlands universitetssjukhus

    NOT_YET_RECRUITING

    Umeå, 90185, Sweden

  • Södersjukhuset

    NOT_YET_RECRUITING

    Stockholm, 11861, Sweden

  • Örebro University hospital

    RECRUITING

    Örebro, 70382, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.